Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 5 versus DELATESTRYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 5 versus DELATESTRYL.
ANDROID 5 vs DELATESTRYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Testosterone ester; binds to androgen receptors, activating gene transcription and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
50 to 200 mg intramuscularly every 2 to 4 weeks.
None Documented
None Documented
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
8 days (terminal); requires 5-6 weeks to reach steady state with weekly dosing
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Urinary (90% as glucuronide and sulfate conjugates, 5% as unchanged drug); fecal (5%)
Category C
Category C
Androgen
Androgen